{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:39:50Z","timestamp":1778510390883,"version":"3.51.4"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Objectives\u2003This study aimed to evaluate the effect of pravastatin to prevent preeclampsia (PE) in pregnant women at a high risk of developing PE and the maternal and perinatal outcomes and the soluble fms-like tyrosine kinase 1\/placental growth factor (sFlt1\/PlGF) ratio.<\/jats:p>\n                  <jats:p>Study Design\u2003This is an open-labeled randomized controlled trial (RCT), a part of INOVASIA (Indonesia Pravastatin to Prevent Preeclampsia study) trial. Pregnant women at a high risk of developing PE were recruited and randomized into an intervention group (40) and a control group (40). The inclusion criteria consisted of pregnant women with positive clinical risk factor and abnormal uterine artery Doppler examination at 10 to 20 weeks' gestational age. The control group received low dose aspirin (80\u2009mg\/day) and calcium (1\u2009g\/day), while the intervention group received additional pravastatin (20-mg twice daily) starting from 14 to 20 weeks' gestation until delivery. Research blood samples were collected before the first dose of pravastatin and before delivery. The main outcome was the rate of maternal PE, maternal\u2013perinatal outcomes, and sFlt-1, PlGF, sFlt-1\/PlGF ratio, and soluble endoglin (sEng) levels.<\/jats:p>\n                  <jats:p>Results\u2003The rate of PE was (nonsignificantly) lower in the pravastatin group compared with the control group (17.5 vs. 35%). The pravastatin group also had a (nonsignificant) lower rate of severe PE, HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome, acute kidney injury, and severe hypertension. The rate of (iatrogenic) preterm delivery was significantly (p\u2009=\u20090.048) lower in the pravastatin group (n\u2009=\u20094) compared with the controls (n\u2009=\u200912). Neonates in the pravastatin group had significantly higher birth weights (2,931\u2009\u00b1\u2009537 vs. 2,625\u2009\u00b1\u2009872\u2009g; p\u2009=\u20090.006), lower Apgar's scores\u2009&lt;\u20097 (2.5 vs. 27.5%, p\u2009=\u20090.002), composite neonatal morbidity (0 vs. 20%, p\u2009=\u20090.005), and NICU admission rates (0 vs. 15%, p\u2009=\u20090.026). All biomarkers show a significant deterioration in the control group compared with nonsignificant changes in the pravastatin group.<\/jats:p>\n                  <jats:p>Conclusion\u2003Pravastatin holds promise in the secondary prevention of PE and placenta-mediated adverse perinatal outcomes by improving the angiogenic imbalance.<\/jats:p>\n                  <jats:p>Key Points<\/jats:p>","DOI":"10.1055\/a-1673-5603","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T20:48:47Z","timestamp":1634676527000},"page":"300-309","source":"Crossref","is-referenced-by-count":22,"title":["INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and Its Effects on sFlt1\/PlGF Levels"],"prefix":"10.1055","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03648970","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Muhammad Ilham Aldika","family":"Akbar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Universitas Airlangga, Mayjen Prof Dr. Moestopo Street No. 47, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Universitas Airlangga Hospital, Mulyorejo Street, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelia","family":"Yosediputra","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Dr. Soetomo General Academic Hospital, Mayjen Prof Dr. Moestopo Street No. 6-8, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raditya E.","family":"Pratama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Ibnu Sina General Hospital, Dr. Wahidin Sudirohusodo Street No243B, Gresik, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur L.","family":"Fadhilah","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Semen Gresik General Hospital, RA. Kartini Street No. 280, Gresik, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulistyowati","family":"Sulistyowati","sequence":"additional","affiliation":[{"name":"Department Obstetrics and Gynecology Blambangan General Hospital, Letkol Istiqlah Street No. 49, Banyuwangi, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariska Z.","family":"Amani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Nadhlatul Ulama, Raya Jemursari Street No. 57, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernawati","family":"Ernawati","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Universitas Airlangga, Mayjen Prof Dr. Moestopo Street No. 47, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Dr. Soetomo General Academic Hospital, Mayjen Prof Dr. Moestopo Street No. 6-8, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erry G.","family":"Dachlan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Universitas Airlangga, Mayjen Prof Dr. Moestopo Street No. 47, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Dr. Soetomo General Academic Hospital, Mayjen Prof Dr. Moestopo Street No. 6-8, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad D.","family":"Angsar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Universitas Airlangga, Mayjen Prof Dr. Moestopo Street No. 47, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Universitas Airlangga Hospital, Mulyorejo Street, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Dr. Soetomo General Academic Hospital, Mayjen Prof Dr. Moestopo Street No. 6-8, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gus","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Universitas Airlangga, Mayjen Prof Dr. Moestopo Street No. 47, Surabaya, Indonesia"},{"name":"Department of Obstetrics and Gynecology Lyell McEwin Hospital, The University of Adelaide, Adelaide, South Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"l2381","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"G J Burton","year":"2019","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.ajog.2015.08.003","article-title":"Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity","volume":"213","author":"C WG Redman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.placenta.2008.11.021","article-title":"Placental stress and pre-eclampsia: a revised view","volume":"30","author":"C WG Redman","year":"2009","journal-title":"Placenta"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2215\/CJN.12081115","article-title":"Preeclampsia: updates in pathogenesis, definitions, and guidelines","volume":"11","author":"E Phipps","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref5","first-page":"12381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"G J Burton","year":"2019","journal-title":"BMJ"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"S Rana","year":"2019","journal-title":"Circ Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","article-title":"Pathogenesis of preeclampsia","volume":"5","author":"B C Young","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"R J Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3346\/jkms.2007.22.5.873","article-title":"Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia","volume":"22","author":"S-Y Kim","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"R J Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3346\/jkms.2007.22.5.873","article-title":"Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia","volume":"22","author":"S Y Kim","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"e4453","DOI":"10.1371\/journal.pone.0004453","article-title":"Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia","volume":"4","author":"A Reddy","year":"2009","journal-title":"PLoS One"},{"issue":"76","key":"ref13","first-page":"168","article-title":"Gestational hypertension and preeclampsia","volume":"133","author":"ACOG","year":"2019","journal-title":"Obstet Gynecol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"6268276","DOI":"10.1155\/2018\/6268276","article-title":"Preeclampsia in 2018: revisiting concepts, physiopathology, and prediction","volume":"2018","author":"J Mayrink","year":"2018","journal-title":"ScientificWorldJournal"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"M A Brown","year":"2018","journal-title":"Hypertension"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jri.2013.12.120","article-title":"Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia","author":"W Ramma","year":"2014","journal-title":"J Reprod Immunol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/bph.12977","article-title":"Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?","volume":"172","author":"A Ahmed","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1042\/BST0371237","article-title":"Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?","volume":"37","author":"A Ahmed","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/bph.12977","article-title":"Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?","volume":"172","author":"A Ahmed","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.preghy.2020.11.014","article-title":"Effects of statins on preeclampsia: a systematic review","volume":"23","author":"A Vahedian-Azimi","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fphar.2017.00247","article-title":"The role of statins in prevention of preeclampsia: a promise for the future?","volume":"8","author":"V Katsi","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","article-title":"The role of statins in the prevention of preeclampsia","volume":"226","author":"D D Smith","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14715\/cmb\/2018.64.10.1","article-title":"Role of statin as inducer of Hmox-1 system in treatment of preeclampsia","volume":"64","author":"R A Putra","year":"2018","journal-title":"Cell Mol Biol"},{"issue":"13","key":"ref24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.106.660134","article-title":"Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1","volume":"115","author":"M Cudmore","year":"2007","journal-title":"Circulation"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1080\/14767058.2021.1879785","article-title":"Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study","volume":"35","author":"M IA Akbar","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial","volume":"127","author":"A Ahmed","year":"2020","journal-title":"BJOG"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2010.15","article-title":"Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia","volume":"33","author":"A Ohkuchi","year":"2010","journal-title":"Hypertens Res"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"M M Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"M M Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"25","key":"ref30","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1080\/14767058.2021.1940940","article-title":"Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study","volume":"35","author":"M J Kupferminc","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1701-2163(16)32656-1","article-title":"Risks of statin use during pregnancy: a systematic review","volume":"29","author":"A Kazmin","year":"2007","journal-title":"J Obstet Gynaecol Can"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"M A Brown","year":"2018","journal-title":"Hypertension"},{"issue":"02","key":"ref33","first-page":"1024","article-title":"Obesity and risk of preeclampsia","volume":"2","author":"H Kanayama N Itoh","year":"2014","journal-title":"Med J Obstet Gynecol"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1515\/jpm-2016-0418","article-title":"Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy","volume":"45","author":"R S Rocha","year":"2017","journal-title":"J Perinat Med"},{"issue":"10","key":"ref38","first-page":"992","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"64355","author":"J L Richard","year":"2006","journal-title":"N Engl J Med"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2125.2007.02905.x","article-title":"Risk of congenital anomalies in pregnant users of statin drugs","volume":"64","author":"B Ofori","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","volume":"10","author":"D G Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","article-title":"Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events","volume":"39","author":"T Hatanaka","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/OGX.0000000000000522","volume":"73","author":"E-V Enrique","year":"2018","journal-title":"Obstetrical & Gynecological Survey"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"M M Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia","volume":"66","author":"F C Brownfoot","year":"2015","journal-title":"Hypertension"},{"issue":"14","key":"ref45","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1055\/s-0040-1713651","article-title":"Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study","volume":"38","author":"M Mendoza","year":"2021","journal-title":"Am J Perinatol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1673-5603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:10:33Z","timestamp":1730794233000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1673-5603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":42,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1673-5603","archive":["Portico","CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741813993.793592106","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.19.21259184","asserted-by":"object"}]},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,19]]},"published":{"date-parts":[[2021,10,19]]}}}